A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients

Inclusion Criteria: * at the age of 18 or more * newly diagnosed within three months as a Chronic Myeloid Leukemia * with positive Philadelphia chromosome and appearance of BCR-ABL transcript * with 0 - 2 of ECOG Performance Status * with normal renal function * with normal hepatic function * able to understand and decide to involve the study Exclusion Criteria: * history of radiation therapy for more than 25% of bone marrow due to other malignant diseases * history of other clinically relevant malignant tumors * with bleeding disorders which are not related to leukemia * evidence of clinically relevant cardiac dysfunction * with severe disease which cannot be regulated by other organs * a previous administration of Imatinib more than a week prior to the first dose. * participation in other drug study(eg. intervention trial) within 30 days prior to the screening visit * HIV-infected * females with pregnancy, childbearing or lactating potential * other reasons determined by investigators